Industry
Biotechnology
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Loading...
Open
17.18
Mkt cap
371M
Volume
59K
High
17.78
P/E Ratio
-4.33
52-wk high
74.49
Low
16.86
Div yield
N/A
52-wk low
14.42
Portfolio Pulse from
February 24, 2025 | 12:45 pm
Portfolio Pulse from
February 04, 2025 | 10:30 pm
Portfolio Pulse from
February 01, 2025 | 3:15 pm
Portfolio Pulse from
January 30, 2025 | 5:15 pm
Portfolio Pulse from
January 28, 2025 | 5:15 pm
Portfolio Pulse from
January 26, 2025 | 5:15 pm
Portfolio Pulse from
January 24, 2025 | 5:15 pm
Portfolio Pulse from
January 22, 2025 | 9:00 pm
Portfolio Pulse from
January 22, 2025 | 12:30 am
Portfolio Pulse from
January 17, 2025 | 1:15 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.